Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Pluvicto is designed to seek out and bind to cancer cells that express PSMA. Once attached, it delivers a small, targeted dose of radiation directly to the cancer cells — killing them while ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion.

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for prostate cancer, according to GlobalData.

Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug, according to a Novartis press release.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

While PLUVICTO is not a cure for mCRPC, men who received PLUVICTO plus standard therapy lived longer and saw their tumors shrink or disappear at higher rates, compared to men who only received ...

Pluvicto pushes earlier in prostate cancer play. From my colleague Allison DeAngelis: Just a couple of months after getting a new approval for its blockbuster prostate cancer drug Pluvicto ...